Promising late-stage trial results lift US pharmaceutical group’s shares almost 15%
US pharmaceutical group says patient in study experienced ‘potential drug-induced liver injury’
Move comes as government seeks to boost UK’s standing as drugs research leader
Acquisitions hold cure for pharma companies’ chronic patent cliff problem
AI unit is boosted by first external funding round led by OpenAI-backer Thrive Capital
The health benefits could be so extreme that it upends the annuity market, hitting retirement incomes and insurers
London-listed drugmaker will establish research centre in Beijing
Academic institutions have frozen new hires and limited PhD places
Pharmaceutical groups are rushing to dominate market that will grow to 900mn people by 2030
Swiss pharma group signs $5.3bn licensing agreement for next-generation treatment made by Zealand Pharma
Pharma group looks to take advantage as Wegovy and Ozempic start to go off patent next year
Mental health treatments face higher regulatory hurdles for approval, warns Imperial College professor
BioArctic is developing a process to allow drugs to cross the layer of cells that protects the brain
Research highlights growing focus on surrounding tissues to help tackle most malignant forms of the disease
Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019
A battle over how to treat childhood obesity is brewing between those in favour and others who warn of the effects on growing bodies
Drugmaker pins hopes on launch of new medicines but key point is to avoid re-traumatising investors
The San Francisco-based start-up plans to get its first drug into trials this year
Analysis of drugs such as Ozempic finds a lower health risk for 42 conditions but a higher rate of disorders such as arthritis
Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers
Verdiva Bio wants to use potential drugs acquired in China to compete in growing obesity market
IDRx tests treatment for digestive system cancer that affects 4,000 to 6,000 people a year in US
Autolus hopes its less gruelling Car-T treatment for a type of leukaemia will allow it to compete with bigger rivals
Regulatory go-ahead marks latest boost for drugmaker’s blockbuster anti-obesity franchise
Treatment for short bowel syndrome fails to win approval from US regulator
